News
IV bevacizumab improves severe bleeding in HHT
Intravenous (IV) bevacizumab “dramatically” improves severe bleeding associated with hereditary hemorrhagic telangiectasia (HHT), according to...
News
Trial protocols redacted by industry sponsors
New research has revealed a lack of public information regarding protocols for industry-sponsored, randomized drug trials in Denmark. First,...
News
No need for structured PE assessment, team says
There is no need for a structured algorithm to rule out pulmonary embolism (PE) in patients who visit the emergency department (ED) for syncope,...
News
Phototherapeutic technology could fight MM, other cancers
Preclinical research suggests that light-triggered, chemotherapy-loaded nanoparticles could treat multiple myeloma (MM) and other malignancies....
News
Zika vaccine candidate receives fast track designation
The US Food and Drug Administration (FDA) has granted fast track designation to TAK-426, a candidate vaccine for Zika virus. TAK-426 is a...
News
IMPDH inhibitors could treat ALL
A mutation that leads to relapse in patients with acute lymphoblastic leukemia (ALL) also causes a weakness that could be exploited to kill...
News
FDA clears assay for myeloma patients
The US Food and Drug Administration (FDA) has granted 510(k) clearance for Sebia’s Hydrashift 2/4 daratumumab immunofixation assay. This in vitro...
News
CHMP recommends approval of emicizumab
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of emicizumab (Hemlibra®), a...
News
Real-world data show risk of major bleeding, stroke with NOACs
LOS ANGELES—A real-world analysis has quantified the risks of stroke and major bleeding in patients with non-valvular atrial fibrillation (NVAF)...
News
T-cell therapy produces durable responses in rel/ref HL
Engineered T cells can produce durable responses in patients with Epstein Barr virus–positive (EBV+), relapsed/refractory Hodgkin lymphoma (HL),...
News
Treatment costs threaten cancer program growth
Treatment costs are the greatest threat to the growth of cancer programs, according to a survey of nearly 300 cancer program administrators and...
News
Technique could aid treatment of CLL
Researchers say they have developed a new technique for assessing chromosomal abnormalities in chronic lymphocytic leukemia (CLL). The team...
News
FDA approves test to diagnose MPNs
The US Food and Drug Administration (FDA) has cleared use of QIAGEN’s ipsogen JAK2 RGQ PCR Kit (ipsogen JAK2 assay) for the diagnosis of all...
News
Adjunct to HSCT receives orphan designation
The European Commission (EC) has granted orphan designation to NLA101 as an adjunct to hematopoietic stem cell transplant (HSCT). NLA101 is a...
News
Low inhibitor rate observed in PUPs with hemophilia A
Researchers have observed a low inhibitor rate in previously untreated patients (PUPs) with severe hemophilia A who received treatment with...